Welcome to our dedicated page for ABEONA THERAPEUTICS SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ABEONA THERAPEUTICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ABEONA THERAPEUTICS's regulatory disclosures and financial reporting.
Abeona Therapeutics’ Chief Commercial Officer Madhav Vasanthavada reported small stock sales primarily for tax purposes. On June 8, he sold 4,170 shares of common stock in open-market transactions at a weighted average price of $5.4295 per share. On June 9, he sold another 5,450 shares at a weighted average price of $5.3042 per share. A footnote explains that these sales were made to cover tax obligations tied to the vesting of restricted stock awards, indicating they are compensation-related rather than discretionary portfolio trades. After these transactions, he directly held 303,451 shares of Abeona common stock.
Abeona Therapeutics CEO Vishwas Seshadri reported selling a total of 56,344 shares of common stock in open-market transactions on June 8 and 9, 2026. According to the disclosure, these sales were made to cover tax obligations associated with the vesting of restricted stock awards.
After these tax-related sales, Seshadri directly owns 1,374,079 shares of Abeona Therapeutics common stock.
ABEO submitted a Rule 144 notice reporting recent dispositions of Common Stock by Joseph Vazzano. The filing lists a sale of 785 shares on 03/16/2026 for $3,737.00 and a sale of 13,421 shares on 06/08/2026 for $71,188.00.
The notice also references Common Stock and Restricted Stock Awards and includes numeric entries of 25,646 and 51,747 in related sections of the form.
ABEO reported a proposed sale of 10,000 shares of Common Stock via Stifel Nicolaus & Company Inc. The filing lists a trade date or filing date of 06/08/2026 and identifies Restricted Stock Awards of 21,334 shares in the securities section. The record shows a prior sale by Madhav Vasanthavada of 5,548 shares on 05/11/2026 for $33,073.00.
ABEO submitted a Form 144 notice reporting a proposed sale of 112,276 shares of Common Stock tied to Restricted Stock Awards, dated 06/05/2026 with an effective filing date of 06/08/2026.
The filing also reports prior transactions: Vishwas Seshadri sold 29,958 shares on 03/31/2026 with an aggregate reported value of $131,363.00. The filing is an SEC notification of proposed resale under equity compensation rules.
ABEO submitted a Form 144 notice reporting a proposed sale of 25,000 shares of Common Stock through Stifel Nicolaus & Company Inc. The filing also lists 51,747 Restricted Stock Awards and indicates an earlier reported sale of 785 shares for $3,737.00 on 03/16/2026. The transaction dates shown include 06/05/2026 and 06/08/2026.
Abeona Therapeutics reported that it held a pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration regarding ABO-701, its engineered T-cell therapy targeting Prostate-Specific Membrane Antigen for prostate cancer. The company believes the meeting was constructive and is still aiming to submit an IND application for ABO-701 in 2027, in line with its prior timeline. Management notes there is no assurance the FDA will not request additional studies or data, or that any eventual IND submission will be accepted or allow clinical trials to begin, and highlights that development plans may change based on FDA feedback, preclinical results, manufacturing considerations, financing, and other risks described in its SEC filings.
Abeona Therapeutics director Mark Alvino reported a bona fide gift of 500 shares of Common Stock. The gift was recorded at a price of $0.00 per share, reflecting a non-market, no‑consideration transfer. Following this disposition, he directly holds 77,065 shares of Abeona Therapeutics common stock.
Abeona Therapeutics director Mark Alvino reported an open-market sale of company stock. He sold 6,500 shares of common stock on May 22, 2026 at a weighted average price of $5.4558 per share, through multiple trades priced between $5.44 and $5.47.
After this transaction, Alvino directly holds 77,565 shares of Abeona Therapeutics common stock. The filing notes that full details of the individual trade prices within the reported range are available upon request.